Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey-Reference-Cited by-同舟云学术

Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey

Published:2022-02-01 Issue:2 Volume:44 Page:e396-e402
ISSN:1077-4114
Container-title:Journal of Pediatric Hematology/Oncology
language:en
Short-container-title:

Author:

Tüfekçi Özlem,Evim Melike Sezgin,Güneş Adalet Meral,Celkan Tiraje,Karapinar Deniz Yilmaz,Kaya Zühre,Baysal Birsen,Baytan Birol,Koçak Ülker,Yilmaz Şebnem,Çinar Suzan,Ören Hale

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference40 articles.

1. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster;Schrappe;Leukemia,2000

2. Treatment of acute lymphoblastic leukemia;Pui;N Engl J Med,2006

3. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia;Moghrabi;Blood,2007

4. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia;Flohr;Leukemia,2008

5. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95;Möricke;Blood,2008

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Use of Flow Cytometry for MRD Detection of B- and T-ALL in Pediatric Patients;Reference Module in Biomedical Sciences;2024

2. A Comprehensive Overview of Recent Advances in Epigenetics in Pediatric Acute Lymphoblastic Leukemia;Cancers;2022-11-01

3. Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives;Frontiers in Immunology;2022-06-13

4. MRD in ALL: Optimization and Innovations;Current Hematologic Malignancy Reports;2022-05-26